Dechra Pharmaceuticals

Europe Pet Supplements Market Report 2023: Focused Insights, Market Dynamics, Competitive Landscape, Trends and Forecasts 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023

The "Europe Pet Supplements Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Pet Supplements Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report provides market size and forecast data for the European pet supplements market, including revenue generated from the sale of pet supplements.
  • It offers a comprehensive overview of the current market scenario in Europe, including market size, anticipated market forecasts, relevant market segmentations, and industry trends for the period 2023-2028.
  • The study examines the current dynamics of the pet supplements market in Europe, covering growth enablers, restraints, and trends.

Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

Retrieved on: 
Tuesday, May 23, 2023

Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC which will see international veterinary group Dechra and ILC Therapeutics develop ILC’s Caniferon product to treat atopic dermatitis in dogs.

Key Points: 
  • Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC which will see international veterinary group Dechra and ILC Therapeutics develop ILC’s Caniferon product to treat atopic dermatitis in dogs.
  • Atopic dermatitis is the most common form of eczema affecting humans and canines, with the global canine market for atopic dermatitis exceeding $1bn.
  • View the full release here: https://www.businesswire.com/news/home/20230523005576/en/
    Scottish biotech ILC Therapeutics has signed a R&D partnership with Dechra Pharmaceuticals PLC (Photo: Business Wire)
    Dechra is a global specialist in veterinary pharmaceuticals and related products.
  • Dr Alan Walker, CEO of ILC Therapeutics, said: “While ILC’s main focus to date has been around human health, the partnership with Dechra is a validation of our technology and the potential to develop products in the animal health market.

Kane Biotech Announces Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 24, 2022

WINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the Company or Kane Biotech) today announced its third quarter 2022 financial results.

Key Points: 
  • WINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the Company or Kane Biotech) today announced its third quarter 2022 financial results.
  • Gross profit for the third quarter of 2022 was $269,740, an increase of 105% compared to $131,665 for the quarter ended September 30, 2021.
  • Detailed financial information about Kane Biotech can be found in its September 30, 2022 Financial Statements and Management Discussion and Analysis on SEDAR and the Companys website.
  • Kane Biotech is pleased to invite all interested parties to participate in a conference call on Thursday, November 24, 2022 at 4:30pm ET to review the financial results and discuss business developments in the period.

Inhalation Anesthesia Global Market Report 2022: Increased Safety for Geriatric Patients Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022

The "Inhalation Anesthesia Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhalation Anesthesia Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the inhalation anesthesia market in 2021.
  • The regions covered in the inhalation anesthesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Therefore, the increasing geriatric population is expected to boost demand for inhalation anesthesia during the forecast period.

Veterinary Pain Management Market worth $2.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 22, 2022

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

Key Points: 
  • In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
  • In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market.
  • The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration.
  • Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications.

Animal Wound Care Market worth $1.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 8, 2022

CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Animal Wound Care Market is projected to grow from USD 1.2 billion in 2022 to USD 1.7 billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Animal Wound Care Market is projected to grow from USD 1.2 billion in 2022 to USD 1.7 billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • The growth in this market is driven by rising demand for animal food products, increasing companion animal market, and surging veterinary healthcare expenditure.
  • In this report, the animal wound care market is segmented on the basis of product, animal type, end users and region.
  • On the basis of region, the animal wound care market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa.

Animal Wound Care Market worth $1.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 8, 2022

CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Animal Wound Care Market is projected to grow from USD 1.2 billion in 2022 to USD 1.7 billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Animal Wound Care Market is projected to grow from USD 1.2 billion in 2022 to USD 1.7 billion by 2027, at a CAGR of 7.3% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • The growth in this market is driven by rising demand for animal food products, increasing companion animal market, and surging veterinary healthcare expenditure.
  • In this report, the animal wound care market is segmented on the basis of product, animal type, end users and region.
  • On the basis of region, the animal wound care market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa.

Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales and Accelerate Pipeline

Retrieved on: 
Wednesday, January 12, 2022

Anivive announces that Dechra has acquired rights to Laverdia-CA1 (verdinexor), a novel treatment for canine lymphoma.

Key Points: 
  • Anivive announces that Dechra has acquired rights to Laverdia-CA1 (verdinexor), a novel treatment for canine lymphoma.
  • Anivive developed Laverdia-CA1 to address the obstacles that commonly prevent dogs from receiving cancer treatment, including cost, convenience and concerns about side effects.
  • This license of Laverdia-CA1 will allow Anivive to accelerate the discovery, development and marketing of additional novel therapies for the unmet need of pets.
  • Using a novel technology and analytics platform, Anivive discovers first-in-class therapeutics for unmet conditions in pets.